- Employees
- 51–200
- Founded
- 2013
- Business Model
- B2B
- Website
- loxooncology.com
- Total Funding
- $57.0M
- Last Round
- $24.0M Series BMay 2014
- Rounds
- 2
- Acquisition Date
- Jan 2019
About
Loxo Oncology was a biopharmaceutical company focused on developing precision oncology medicines targeting cancers driven by specific genetic abnormalities. Its pipeline included larotrectinib (VITRAKVI), the first FDA-approved tumor-agnostic TRK inhibitor. The company was acquired by Eli Lilly in February 2019 for approximately $8 billion.
Summary
Loxo Oncology is a Biotech company based in United States, founded in 2013. It has raised $57.0M in total across 2 rounds, most recently a $24.0M Series B round in May 2014. Investors include Aisling Capital, Eli Lilly and New Enterprise Associates.
Funding History
Sign up to view the funding chart
Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.
Jan 2019
Sign up to see all 4 rounds
Series A through Acquisition — per-round amounts, valuations, and who invested in each round.
Investors
Similar Companies
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Avenzo is a San Diego, CA-based biopharma company to in-license and develop the next generation o...
Clinical-stage biopharmaceutical company founded in 2015 developing best-in-class cancer therapeu...
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Simtra provides pharmaceutical and biotech clients development and manufacturing services for ste...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/loxo-oncology"><img src="https://indexed.vc/api/badge/company/loxo-oncology" alt="Loxo Oncology on Indexed.vc" width="260" height="76" /></a>